Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has announced the acceptance of a new drug application for Anlotinib Hydrochloride Capsules combined with chemotherapy, marking a significant step in treating advanced soft tissue sarcoma. This innovative combination therapy has shown promising efficacy in clinical trials, potentially offering hope to patients less responsive to conventional treatments. The company’s ongoing investment in research and development underscores its commitment to advancing cancer treatment options.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
